Momenta Pharmaceuticals (MNTA)
Like Sagent Pharmaceuticals, Momenta Pharmaceuticals (MNTA) is a generic drugmaker. And also like Sagent, priced at $16.14 per share, MNTA stock is easily put into the cheap stocks category.
Unlike Sagent, however, Momenta Pharmaceuticals isn’t profitable, hasn’t been since 2011 and probably won’t be anytime in the foreseeable future.
So what makes MNTA stock one of the more buy-able cheap stocks in this sector? Because Momenta isn’t your run-of-the-mill generic pharmaceutical company. The drugmaker is at the head of the class when it comes to making generic biosimilars… generic versions of complex drugs that are derived from living organisms. It’s not an easy thing to do, and competition within the arena (generic or not) can be fierce.
But, given the pharma industry’s migration towards this more potent class of medicines, MNTA stock has plenty working in its favor for the long haul.